Status:
COMPLETED
Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin
Lead Sponsor:
Samsung Medical Center
Conditions:
Curatively Resected Stage III Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.
Detailed Description
To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for ...
Eligibility Criteria
Inclusion
- aged 18 or older
- curatively resected colon adenocarcinoma
- pathologically staged III
- adequate performance status
- adequate major organ functions
- to be treated with adjuvant FOLFOX chemotherapy
- written informed consent
Exclusion
- those who disagree the study
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00977717
Start Date
September 1 2008
End Date
April 1 2010
Last Update
April 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135 710